131 related articles for article (PubMed ID: 25242760)
21. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
[TBL] [Abstract][Full Text] [Related]
22. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
[TBL] [Abstract][Full Text] [Related]
23. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
24. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
Inrig JK; Barnhart HX; Reddan D; Patel UD; Sapp S; Califf RM; Singh AK; Szczech LA
Am J Kidney Dis; 2012 Sep; 60(3):390-401. PubMed ID: 22537421
[TBL] [Abstract][Full Text] [Related]
25. [Switch from Darbepoetin-alpha to Epoetin-alpha: cost and efficacy comparison for haemodialytic patients over one year follow-up in a single centre].
Orazi E
G Ital Nefrol; 2008; 25(2):223-6. PubMed ID: 18350502
[TBL] [Abstract][Full Text] [Related]
26. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
Berger A; Edelsberg J; Kallich J; Oster G
Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
[TBL] [Abstract][Full Text] [Related]
27. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients.
Harzallah A; Zouaghi K; Dridi A; Boubaker K; Beji S; Ayari M; El Younsi F; Moussa FB; Kheder A
Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):78-82. PubMed ID: 25579720
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
Haag-Weber M; Vetter A; Thyroff-Friesinger U;
Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
[TBL] [Abstract][Full Text] [Related]
30. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease.
Papatheofanis F; Bookhart BK; Muser E; Piech CT
J Occup Environ Med; 2008 May; 50(5):584-9. PubMed ID: 18469628
[TBL] [Abstract][Full Text] [Related]
31. Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa.
Debus J; Drings P; Baurecht W; Angermund R
Radiother Oncol; 2014 Jul; 112(1):23-9. PubMed ID: 25129551
[TBL] [Abstract][Full Text] [Related]
32. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
33. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients.
Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
Ther Apher Dial; 2014 Oct; 18(5):404-13. PubMed ID: 24571446
[TBL] [Abstract][Full Text] [Related]
34. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
36. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
37. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
38. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
Malyszko J; Glowinska I; Mysliwiec M
Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
[TBL] [Abstract][Full Text] [Related]
39. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
Spaepen E; Demarteau N; Van Belle S; Annemans L
Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
[TBL] [Abstract][Full Text] [Related]
40. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
